Expanding the Role of PARP Inhibitors in Ovarian Cancer - priME Oncology
Webcast
Webcast

Expanding the Role of PARP Inhibitors in Ovarian Cancer

The Ever-Changing Treatment Landscape

Not a member of My prIME? Join now for instant access.

View the webcast from our satellite symposium to get the latest information on PARP inhibitors for ovarian cancer from leading experts in the field, including the current treatment landscape, recently presented data for patients with newly-diagnosed disease, potential future directions under investigation, and practical implications for patient management.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Feb 28, 2019

Expiration Date

Feb 28, 2020

Look how far we’ve come: The current role of PARP inhibitors in the management of ovarian cancer
Jonathan Ledermann, BSC, MD, FRCP

PARP inhibitors in newly diagnosed advanced BRCAm ovarian cancer: The new standard?
Susana Banerjee, MBBS, MA, PhD, FRCP

A look to the future: What’s next for PARP inhibitors?
Isabelle Ray-Coquard, MD, PhD

Putting the data into practice: Practical issues with the use of PARP inhibitors
Nicoletta Colombo, MD, PhD

prIME Points™
Jonathan Ledermann, BSc, MD, FRCP

  • Susana Banerjee, MBBS, MA, PhD, FRCPRoyal Marsden Hospital
    Institute of Cancer Research
    London, United Kingdom
  • Nicoletta Colombo, MD, PhDUniversity of Milan–Bicocca
    European Institute of Oncology
    Milan, Italy
  • Jonathan Ledermann, BSc, MD, FRCPUCL Cancer Institute
    London, United Kingdom
  • Isabelle Ray-Coquard, MD, PhDCentre Léon Bérard
    Lyon, France

The educational activity is specifically designed for medical oncologists, gynecologists, and other healthcare providers involved in the management of patients with ovarian cancer.

After successful completion of this educational activity, participants should be able to:

  • Describe recent key clinical findings from trials investigating PARP inhibitors in both the first-line maintenance setting and recurrent disease
  • Identify important ongoing clinical trials investigating PARP inhibitors across the treatment continuum, both as single agents and in combination with other targeted or immunologic therapies
  • Implement strategies to address practical challenges associated with PARP inhibitors, such as patient selection and adverse events

This educational activity is supported by a grant from AstraZeneca.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Banerjee has disclosed receipt of grants/research support from AstraZeneca and Janssen Cilag. She has also received honoraria or consultation fees from AstraZeneca, Clovis, GamaMabs, Merck, PharmaMar, Roche, Seattle Genetics, and Tesaro. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Colombo has disclosed that she has received honoraria or consultation fees from Advaxis, Amgen, AstraZeneca, Clovis, Merck Sharp & Dohme, Pfizer, PharmaMar, Roche, and Tesaro. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Ledermann has disclosed that he has received grants or research support from AstraZeneca and Merck Sharp & Dohme. He has also received honoraria or consultation fees from AstraZeneca, Clovis, Merck Sharp & Dohme, Pfizer, Roche, and Seattle Genetics, and participated in sponsored speaker’s bureaus for AstraZeneca and Clovis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Ray-Coquard has disclosed that she has received honoraria or consultation fees from AstraZeneca, Clovis, PharmaMar, Roche, and Tesaro. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed no relevant financial relationships.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.